Actionable news
All posts from Actionable news

Prospectuses and communications, business combinations


On behalf of our entire management team, we are excited about the merger with TriVascular and we look forward to welcoming you to our family in 2016! We have many exciting things to look forward to over the coming days, weeks and years. I am sure you have many questions about the future and we are committed to answering them together with your TriVascular leadership team.

This merger will combine two innovation leaders in endovascular AAA, both of which are focused exclusively on the aorta and on developing and providing revolutionary aortic treatments. Together with TriVascular, Endologix will be uniquely positioned to offer customers an unmatched product offering designed to treat a wide range of AAA patient anatomies. The combination of the AFX ® , Ovation ® , and Nellix ® 1 platforms will represent the broadest product offering and indications in AAA and supports the continuing Value of both companies to Always put the patient first.

Together, Endologix and TriVascular will have a deep pipeline of new products, which are protected by a significant patent portfolio. These technologies have been developed together with physicians around the world and demonstrate another shared Value of physician-driven innovation. This, combined with dedicated and talented employees like you, will enable us to develop, manufacture and support groundbreaking solutions for the endovascular treatment of aortic disease.

The merger will also expand our teams and enable us to partner with more physicians around the world to treat more patients. As a larger company, we will have more resources to focus on aortic disease and more people dedicated to making a difference. I look forward to working with you to build a great company focused on revolutionary aortic treatments.


John McDermott

Chairman and Chief Executive Officer, Endologix

2 Musick

Irvine, CA 92618


Endologix and TriVascular will remain separate operational entities until close of transaction. Until closing, Endologix will not offer TriVascular products.